AMLX — Amylyx Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $119.30m
- -$252.07m
- $380.79m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.43 | 0.65 | 0.285 | 22.2 | 381 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 19.2 | 355 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 15 | 39.7 | 83 | 224 | 342 |
Operating Profit | -13.6 | -39 | -82.7 | -201 | 38.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.7 | -42.3 | -87.9 | -198 | 54.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13.7 | -42.3 | -87.9 | -198 | 49.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -13.7 | -42.3 | -87.9 | -198 | 49.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13.7 | -42.3 | -87.9 | -198 | 49.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.243 | -0.749 | -1.56 | -3.39 | 0.704 |
Dividends per Share |